178 related articles for article (PubMed ID: 21450091)
1. Prediction of outcome after diagnosis of metachronous contralateral breast cancer.
Alkner S; Bendahl PO; Fernö M; Manjer J; Rydén L
BMC Cancer; 2011 Mar; 11():114. PubMed ID: 21450091
[TBL] [Abstract][Full Text] [Related]
2. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
3. Patterns of metastasis in women with metachronous contralateral breast cancer.
Vichapat V; Garmo H; Holmberg L; Fentiman IS; Tutt A; Gillett C; Lüchtenborg M
Br J Cancer; 2012 Jul; 107(2):221-3. PubMed ID: 22735901
[TBL] [Abstract][Full Text] [Related]
4. Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer.
Tutzauer J; Sjöström M; Bendahl PO; Rydén L; Fernö M; Leeb-Lundberg LMF; Alkner S
PLoS One; 2020; 15(4):e0231786. PubMed ID: 32302351
[TBL] [Abstract][Full Text] [Related]
5. Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.
Prater J; Valeri F; Korol D; Rohrmann S; Dehler S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):365-71. PubMed ID: 26298838
[TBL] [Abstract][Full Text] [Related]
6. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
Yoon TI; Kwak BS; Yi OV; Kim S; Um E; Yun KW; Shin HN; Lee S; Sohn G; Chung IY; Kim J; Ko BS; Lee JW; Son BH; Ahn SH; Kim HJ
Breast Cancer Res Treat; 2019 Feb; 173(3):657-665. PubMed ID: 30377870
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
[TBL] [Abstract][Full Text] [Related]
8. Metachronous contralateral breast cancer as first event of relapse.
de la Rochefordière A; Mouret-Fourme E; Asselain B; Scholl SM; Campana F; Broët P; Fourquet A
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):615-21. PubMed ID: 8948346
[TBL] [Abstract][Full Text] [Related]
9. [Contralateral breast cancer: metastasis or second primary cancer?].
Broët P; de la Rochefordière A; Scholl SM; Fourquet A; Mosseri V; Durand JC; Pouillart P; Asselain B
Bull Cancer; 1996 Oct; 83(10):870-6. PubMed ID: 8952638
[TBL] [Abstract][Full Text] [Related]
10. Relation of risk of contralateral breast cancer to the interval since the first primary tumour.
Rubino C; Arriagada R; Delaloge S; Lê MG
Br J Cancer; 2010 Jan; 102(1):213-9. PubMed ID: 19920826
[TBL] [Abstract][Full Text] [Related]
11. Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients.
Courdi A; Chamorey E; Ferrero JM; Hannoun-Lévi JM
Radiother Oncol; 2013 Aug; 108(2):259-65. PubMed ID: 23891092
[TBL] [Abstract][Full Text] [Related]
12. Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast cancer.
Sandberg ME; Alkner S; Hartman M; Eloranta S; Rydén L; Ploner A; Adami HO; Hall P; Czene K
Int J Cancer; 2013 May; 132(10):2388-94. PubMed ID: 23034813
[TBL] [Abstract][Full Text] [Related]
13. Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
Alkner S; Tang MH; Brueffer C; Dahlgren M; Chen Y; Olsson E; Winter C; Baker S; Ehinger A; Rydén L; Saal LH; Fernö M; Gruvberger-Saal SK
Breast Cancer Res; 2015 Aug; 17(1):102. PubMed ID: 26242876
[TBL] [Abstract][Full Text] [Related]
14. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study.
Vichapat V; Garmo H; Holmqvist M; Liljegren G; Wärnberg F; Lambe M; Fornander T; Adolfsson J; Lüchtenborg M; Holmberg L
J Clin Oncol; 2012 Oct; 30(28):3478-85. PubMed ID: 22927521
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for contralateral breast cancer in Chennai (Madras), India.
Gajalakshmi CK; Shanta V; Hakama M
Int J Epidemiol; 1998 Oct; 27(5):743-50. PubMed ID: 9839728
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses.
Vichapat V; Garmo H; Holmberg L; Fentiman IS; Tutt A; Gillett C; Lüchtenborg M
Breast Cancer Res Treat; 2011 Nov; 130(2):609-18. PubMed ID: 21671018
[TBL] [Abstract][Full Text] [Related]
17. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease.
Heron DE; Komarnicky LT; Hyslop T; Schwartz GF; Mansfield CM
Cancer; 2000 Jun; 88(12):2739-50. PubMed ID: 10870056
[TBL] [Abstract][Full Text] [Related]
18. Incidence of metachronous contralateral breast cancer in Denmark 1978-2009.
Rasmussen CB; Kjær SK; Ejlertsen B; Andersson M; Jensen MB; Christensen J; Langballe R; Mellemkjær L
Int J Epidemiol; 2014 Dec; 43(6):1855-64. PubMed ID: 25326461
[TBL] [Abstract][Full Text] [Related]
19. Contralateral breast cancer: clinical characteristics and impact on prognosis.
Healey EA; Cook EF; Orav EJ; Schnitt SJ; Connolly JL; Harris JR
J Clin Oncol; 1993 Aug; 11(8):1545-52. PubMed ID: 8336193
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways.
Vichapat V; Gillett C; Fentiman IS; Tutt A; Holmberg L; Lüchtenborg M
Eur J Cancer; 2011 Sep; 47(13):1919-27. PubMed ID: 21658939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
